From a patient outcomes perspective, how well-defined are the predictive effects of the drug-sensitive EGFR mutations-- Exon19 and 21 deletions and L858R--in patients with NSCLC?

From a patient outcomes perspective, how well-defined are the predictive effects of the drug-sensitive EGFR mutations-- Exon19 and 21 deletions and L858R--in patients with NSCLC?

From a patient outcomes perspective, how well-defined are the predictive effects of the drug-sensitive EGFR mutations— Exon19 and 21 deletions and L858R—in patients with NSCLC?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Paul Mitchell, BHB, MBChB, FRACP, MD

Paul Mitchell, BHB, MBChB, FRACP, MD

Associate Professor
Senior Specialist
Austin Health Cancer Services
Director, North Eastern Metropolitan Integrated Cancer Services (NEMICS)
Melbourne, Australia